Viral Biofilms: Hijacking T Cell Extracellular Matrix to Regulate HIV-1 Spread? (TRANSBioHIV)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01895920|
Recruitment Status : Completed
First Posted : July 11, 2013
Last Update Posted : February 27, 2018
|Condition or disease||Intervention/treatment||Phase|
|HIV Infection||Other: Blood sample||Not Applicable|
The investigators' preliminary data indicate that besides " free " infectious viral particles, HIV-1 infected cluster of differentiation 4 (CD4+) lymphocytes also produce extracellular viral assemblies wrapped in an extracellular matrix cocoon and tightly bound to the surface of the cell. Importantly, these structures are infectious, transferred to target cells upon intercellular contacts and they are key role in HIV-1 spread between T lymphocytes. HIV-1 viral biofilm could be important not only for direct transmission of the virions but also for " trans-infection ", a process our objectives are:
- to better characterize the molecular composition and the architecture of this biofilm (using proteomics, glycomic superresolution cell imaging approaches) with regard to its properties (infectivity, adhesiveness, protection of virions) and to determine whether cells from infected patients produce such structures.
- to delineate the viral factors regulating the formation of these new infectious structures (with a particular attention on Tat, Vpu and Nef HIV-1 encoded using mutant viruses or expression vectors).
- to investigate the lymphocyte pathways regulating the viral biofilms formation and composition in extracellular matrix (ECM) proteins (using quantitative polymerase chain reaction (qPCR) and siRNA).
- to determine whether those viral biofilms are involved in HIV-1 transmission by transinfection
- to study the contribution of those infectious structures and the dynamics of their transmission in lymph nodes.
This project may contribute to decipher the role of viral biofilms in HIV-1 transmission. Ultimately, we intend to determine how the interference of retroviral infections with T cell activation pathways modulates the pattern of ECM production by T cells, tuning viral biofilm composition and regulating viral dissemination.
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Actual Study Start Date :||January 2013|
|Actual Primary Completion Date :||February 2018|
|Actual Study Completion Date :||February 2018|
Experimental: HIV infection
20 HIV infected subjects
Other: Blood sample
- The percentage of HIV positive patients with cells producing biofilms. [ Time Frame: 2 years ]
- The number of cells with biofilms identified among the HIV positive patients presenting such structures. [ Time Frame: 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01895920
|Service de Médecine Interne, CHU Kremlin-Bicêtre|
|Le Kremlin Bicêtre, France, 94270|